The Biospecimen and Pathology Core (Core B) is crucial for all Penn/Wistar SPORE in Skin Cancer activities. It fully utilizes the infrastructures at the Penn/Wistar and addresses research needs for melanoma patient biospecimens of all the SPORE projects that are not met by current shared facilities at these institutions. Standardized procedures for procurement, processing, storage, quality control, histopathologic evaluation and distribution of samples will ensure optimal utilization and distribution of limited tissue samples according to the guidelines established by the Tissue and Resource Allocation Committee. In addition to collecting, storing and distributing a wide range of biospecimens, the Core maintains a comprehensive tissue database (Labvantage LIMS database) that includes detailed pathologic characteristics and essential clinical data including family history, current therapies of patients, tissue type, amount of stored tissue, distribution log associated with each collected specimen (tissue or blood), and results of molecular (or other analytic) studies generated from these biospecimens. The close relationship with the Biostatistics Core will allow for efficient analysis of the data produced by the different SPORE projects. Leadership for the Core will be shared by a senior dermatopathologist with expertise in melanoma diagnosis and translational research, including histopathologic evaluation, molecular analysis and quality-control procedures as well as a senior pathologist with expertise in tissue collection, database design and bioinformatics. The core interacts extensively with investigators in each project, and shared facilities of the Penn/Wistar Cancer Centers. The services of the Core B enhance the efficient operation of the translational studies by SPORE investigators in a cost-effective manner, and expedite the application of discoveries at the bench to clinical practice, and clinical results to basic research.

Public Health Relevance

The Biospecimen and Pathology Core is a required Core that serves the Penn/Wistar SPORE in Skin Cancer by providing well annotated high quality biospecimens. The Core will function as a hub to procure, process, track, store and distribute well annotated biospecimens including quality controls.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA174523-05
Application #
9542740
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Yuan, Jiao; Hu, Zhongyi; Mahal, Brandon A et al. (2018) Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 34:549-560.e9
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Perego, M; Maurer, M; Wang, J X et al. (2018) A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene 37:302-312
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Duperret, Elizabeth K; Trautz, Aspen; Ammons, Dylan et al. (2018) Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice. Clin Cancer Res 24:1190-1201
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102

Showing the most recent 10 out of 89 publications